Home » Stocks » SQZ

SQZ Biotechnologies Company (SQZ)

Stock Price: $24.24 USD -1.93 (-7.37%)
Updated Jan 25, 2021 4:00 PM EST - Market closed
Market Cap 620.64M
Revenue (ttm) 22.82M
Net Income (ttm) -38.71M
Shares Out 23.97M
EPS (ttm) -1.62
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 25
Last Price $24.24
Previous Close $26.17
Change ($) -1.93
Change (%) -7.37%
Day's Open 26.00
Day's Range 24.01 - 26.00
Day's Volume 24,635
52-Week Range 13.25 - 34.58


Hide News
Business Wire - 2 months ago

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE:SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that Armon Sharei, PhD, ch...

Seeking Alpha - 2 months ago

The IPO market is taking a break during the shortened Thanksgiving week, with just one IPO and two SPACs scheduled to raise $900 million. Russian e-commerce company Ozon Holdings plans to rais...

Other stocks mentioned: ALGM, AVIR, BDSX, GATO, GLTO, LESL, LU, MAX, ROOT
Business Wire - 2 months ago

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ) (“SQZ”) today announced the pricing of its initial public offering of 4,411,765 shares of common stock at a public of...

About SQZ

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops transformative cell therapies for patients with cancer, infectious diseases, and other serious conditions. The company's lead product candidate, SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. Its additional p... [Read more...]

IPO Date
Oct 30, 2020
Armon Sharei
Stock Exchange
Ticker Symbol
Full Company Profile

Financial Performance

In 2019, SQZ's revenue was $20.11 million, an increase of 58.73% compared to the previous year's $12.67 million. Losses were -$32.20 million, 67.3% more than in 2018.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for SQZ stock is "Strong Buy." The 12-month stock price forecast is 38.33, which is an increase of 58.13% from the latest price.

Price Target
(58.13% upside)
Analyst Consensus: Strong Buy